CIK: 0001704132 · Show all filings
Period: Q4 2019 (← Previous) (Next →)
Filing Date: Feb 14, 2020
Total Value ($000): $231,764 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Aerie Pharmaceuticals, Inc. | 1,501,400 | $36,289 | 15.7% | $24.60 | — | COM | 00771V108 |
| — | The Medicines Company | 403,217 | $34,249 | 14.8% | $42.94 | — | COM | 584688105 |
| INSM | Insmed Incorporated | 1,429,518 | $34,137 | 14.7% | $26.85 | -24.2% | COM | 457669307 |
| CYTK | Cytokinetics Incorporated | 2,398,970 | $25,453 | 11.0% | $8.13 | +26.4% | COM NEW | 23282W605 |
| FULC | Fulcrum Therapeutics, Inc. | 1,500,000 | $24,960 | 10.8% | $11.06 | -13.6% | COM | 359616109 |
| — | Myokardia, Inc. | 260,370 | $18,977 | 8.2% | $47.74 | — | COM | 62857M105 |
| VYGR | Voyager Therapeutics, Inc. | 830,565 | $11,586 | 5.0% | $21.95 | — | COM | 92915B106 |
| ABUS | Arbutus BioPharma Corp. | 3,705,128 | $10,300 | 4.4% | $1.62 | 0.0% | COM | 03879J100 |
| ASND | Ascendis Pharma A/S | 68,981 | $9,597 | 4.1% | $40.06 | — | SPONSORED ADR | 04351P101 |
| — | OptiNose, Inc. | 870,766 | $8,028 | 3.5% | $15.00 | — | COM | 68404V100 |
| SIBN | SI-BONE, Inc. | 308,183 | $6,626 | 2.9% | $18.59 | -3.5% | COM | 825704109 |
| ALEC | Alector, Inc. | 353,462 | $6,090 | 2.6% | $18.92 | -10.1% | COM | 014442107 |
| — | CymaBay Therapeutics, Inc. | 2,315,016 | $4,537 | 2.0% | $8.13 | — | COM | 23257D103 |
| KURA | Kura Oncology, Inc. | 68,000 | $935 | 0.4% | $14.82 | 0.0% | COM | 50127T109 |